ALSF Childhood Cancer Research Grants
With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,500 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
Project Title | Institution / Principal Investigator(s) | Grant Type | Year | State |
---|---|---|---|---|
A Novel Target for Neuroblastoma Treatment | Beckman Research Institute of City of Hope / Linda Malkas, Ph.D. | Reach Grants | 2014 | California |
Combining Oncolytic Vaccinia Virus with GD2.CAR-modified Vaccinia Virus-specific T-cells for the Treatment of Relapsed Neuroblastoma and Sarcoma | Baylor College of Medicine / Cliona Rooney, PhD | Reach Grants | 2013 | Texas |
Targeting Novel Pediatric-Specific FLT3 Mutations | Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD,PhD | Reach Grants | 2015 | Washington |
Novel Therapy for Pediatric Leukemia Patients with NUP98 Translocations | The Regents of the University of Michigan / Jolanta Grembecka, PhD | Reach Grants | 2022 | Michigan |
Astatine-211 Meta-Astatobenzylguanidine ([211At]MABG) Targeted Radiotherapy for Disseminated Neuroblastoma | Children’s Hospital of Philadelphia / John Maris, MD | Reach Grants | 2016 | Pennsylvania |
Targeting PLK1 as a Common Mechanism in Ph-like ALL | University of Texas M.D. Anderson Cancer Center / Joya Chandra, PhD | Reach Grants | 2016 | Texas |
Immunotherapy for Pediatric Atypical Teratoid/Rhabdoid Tumor | Baylor College of Medicine / William Decker, PhD | Reach Grants | 2013 | Texas |
Stapled Peptide PROTAC: A 3-in-1 Treatment for Pediatric Solid Tumors | Dana-Farber Cancer Institute / Loren Walensky, MD/PhD | Reach Grants | 2021 | Massachusetts |
B-lapachone as a Novel Targeted Therapy for ATRTs and other Pediatric Cancers | University of Texas Southwestern Medical Center / James Amatruda, MD, PhD | Reach Grants | 2013 | Texas |
Phase I Study of Lentivirus Engineered Autologous AML Cells Expressing IL-12 in Children and Young Adults with Relapsed AML | Children’s Hospital of Wisconsin - Milwaukee / Michael Burke, MD & Jeffrey Medin, MD/PhD | Reach Grants | 2017 | Wisconsin |